Drug Profile
AS 601811
Latest Information Update: 12 Mar 2008
Price :
$50
*
At a glance
- Originator Merck Serono
- Class
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne; Benign prostatic hyperplasia; Hirsutism; Male pattern baldness; Prostate cancer
Most Recent Events
- 29 Nov 2004 Suspended - Phase-I for Acne in Switzerland (PO)
- 29 Nov 2004 Suspended - Phase-I for Benign prostatic hyperplasia in Switzerland (PO)
- 29 Nov 2004 Suspended - Phase-I for Hirsutism in Switzerland (PO)